Kyntra Bio, Inc. · NASDAQ:KYNB
Kyntra Bio — Q1 2026 Earnings Presentation
20 slides from Kyntra Bio's earnings presentation, May 11, 2026
Slide 1: First Quarter 2026 Financial Results
First Quarter 2026 Financial Results May 11, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements inclu
Slide 3: KYNB Investment Highlights
KYNB Investment Highlights Advancing mid- and late-stage assets in prostate cancer and rare disease; cash runway into 2028 FG-3246 & FG-3180: Attractive Assets in Prostate Cancer, Phase 2 Trial Enrolling • FG-3246, a potential first-in-class, CD46 targeting ADC, with a validated payload, clinically
Slide 4: FG-3246 & FG-3180 Program
Kynira BIO FG-3246 & FG-3180 Program
Slide 5: CD46 as a Novel Tumor Selective Target in mCRPC
CD46 as a Novel Tumor Selective Target in mCRPC CD46 • Multi-functional protein, overexpressed in cancer • Negatively regulates the complement system and helps tumors evade complement- dependent cytotoxicity • Highly expressed in mCRPC and other solid tumors with limited expression in normal tissues
Slide 6: Targeting a Novel Epitope of CD46 Has Therapeutic and Diagnostic Potential
Targeting a Novel Epitope of CD46 Has Therapeutic and Diagnostic Potential FG-3246 FG-3180 PET Therapeutic Imaging Agent Targeting antibody + MMAE payload Targeting antibody + 89Zr tracer YS5 is a fully-human, full length, Demonstrated specific uptake in CD46 YS5 antibody: Offers an androgen recepto
Slide 7: FG-3246 Demonstrated Meaningful Monotherapy Clinical Activity in 5L+ mCRPC Patients
FG-3246 Demonstrated Meaningful Monotherapy Clinical Activity in 5L+ mCRPC Patients Phase 1 dose escalation and expansion study results in biomarker unselected and heavily pre-treated patient population with median of 5 prior lines of therapy Efficacy analysis included 40 patients from the 8.7 7.5 d
Slide 8: Encouraging Anti-Tumor Activity in Phase 1b/2 Study of FG-3246 with Enzalutamide
Encouraging Anti-Tumor Activity Observed in the Phase 1b/2 Investigator-Initiated Study of FG-3246 in Combination with Enzalutamide in mCRPC Phase 1b/2 results in biomarker unselected patients, Phase 1b/2 results in patients who progressed majority of who progressed on ≥2 prior ARPIs on 1 prior ARPI
Slide 9: Higher Tumor Uptake of FG-3180 (PET46) was Associated with PSA50 Response
Higher Tumor Uptake of FG-3180 (PET46) was Associated with PSA50 Response PSA50 Response P-value Yes (n=7) No (n=16) 11.68 9.24 SUVmax-ave [9.91-13.88] [7.98-10.64] 0.109 9.57 7.58 SUVmax-ave/ SUVmean blood pool [9.24-11.93] [6.66-9.80] 0.053 Results demonstrate FG-3180’s potential as PET imaging bi
Slide 10: FG-3246 and FG-3180 Phase 2 Monotherapy Trial Initiated
FG-3246 and FG-3180 Phase 2 Monotherapy Trial Initiated Interim results expected in 4Q 2026 Phase 2 - FG-3246 Dose Optimization in Post-ARPI, Pre-Chemo mCRPC, All Comers (US only) Primary Endpoint: Optimal dose for Phase 3 based on efficacy, safety, and PK Expected Secondary Endpoints: rPFS, PSA50,
Slide 11: Phase 2 Monotherapy Trial: Three Main Design Elements Driving Potential for Increasing rPFS
FG-3246 Phase 2 Monotherapy Trial: Three Main Design Elements Driving the Potential for Increasing rPFS versus Phase 1 Monotherapy Study (>8.7 months) Further validated by Phase 1b/2 Combination IST Use of three of the Use of primary Moving upline to patients highest doses (1.8mg/kg; prophylaxis G-C
Slide 12: Strong Enrollment Momentum and Highly Engaged Sites in the Phase 2 Monotherapy Study
Strong Enrollment Momentum and Highly Engaged Sites in the Phase 2 Monotherapy Study Clinical Sites Currently Activated and in Startup Activated 21 In Startup 3 Interim analysis expected in 4Q 2026 12
Slide 13: Roxadustat Program
Kynira BIO Roxadustat Program
Slide 14: Anemia Associated with Lower-Risk MDS Represents a Significant Opportunity
Anemia Associated with Lower-Risk MDS Represents a Significant Opportunity Anemia is the hallmark symptom of MDS that gives rise to significant morbidity ~75K patients live with MDS in the U.S. Prevalence, United 58K States, 2022 Patients are ~90% suffering from anemia and its 75K LR-MDS negative im
Slide 15: Anemia of LR-MDS: Phase 3 Development Opportunity Based on MATTERHORN Post Hoc Results
Anemia of LR-MDS: Phase 3 Development Opportunity Based on Post Hoc Subgroup Results from MATTERHORN Phase 3 Trial In patients with high transfusion burden1, roxadustat showed promising TI benefits compared to placebo No. of patients with Roxadustat Placebo 8-wk RBC TI 8-wk RBC TI response (% [95% C
Slide 16: Roxadustat May Elevate the Standard of Care in 2L+ LR-MDS-Anemia
Roxadustat May Elevate the Standard of Care in 2L+ LR-MDS-Anemia Target indication: Treatment of anemia in Del(5q) (~10%) RS+ RS- (30-40%) (50-60%) patients with LR-MDS who 1L Lenalidomide Luspatarcept ESA1 are refractory to, intolerant Luspatercept to, or ineligible for, prior ESA treatment 2L+ Len
Slide 17: Potential Pivotal Phase 3 Trial Overview
Potential Pivotal Phase 3 Trial Overview Currently exploring the opportunity to develop internally or with a strategic partner Patient Population Safety • High transfusion burden: Patients requiring ≥ 4 pRBC Management of potential thrombotic risk through: units in two consecutive 8-week periods pri
Slide 18: Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS
Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS • Significant unmet need despite recent approvals Substantial unmet need in • Opportunity for new therapeutic agents that are more effective in RS- patients LR-MDS anemia • No other oral treatments for anemia of LR-MDS commercia
Slide 19: Financial Results
Kynira BIO Financial Results
Slide 20: Thank You
Thank You For more information contact ir@kyntrabio.com NASDAQ: KYNB